BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 2770934)

  • 1. High dose alpha-2-recombinant interferon in the treatment of malignant lymphoproliferative diseases. A pilot study.
    Opat P; Drbal J; Vyzula R
    Neoplasma; 1989; 36(4):489-94. PubMed ID: 2770934
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant alpha interferon in the treatment of low-grade non-Hodgkin's lymphoma: results of a cooperative phase II trial in 31 patients.
    Mantovani L; Guglielmi C; Martelli M; Chierichini A; Deriu L; Sertoli MR; Ardizzoni A; Mandelli F
    Haematologica; 1989; 74(6):571-5. PubMed ID: 2628239
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Interferon-alpha therapy in non-Hodgkin's lymphoma].
    Fridrik MA
    Wien Med Wochenschr; 1993; 143(16-17):429-34. PubMed ID: 8273367
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I study of involved-field radiotherapy preceding autologous stem cell transplantation for patients with high-risk lymphoma or Hodgkin's disease.
    Dawson LA; Saito NG; Ratanatharathorn V; Uberti JP; Adams PT; Ayash LJ; Reynolds CM; Silver SM; Schipper MJ; Lichter AS; Eisbruch A
    Int J Radiat Oncol Biol Phys; 2004 May; 59(1):208-18. PubMed ID: 15093918
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alpha-interferon as maintenance drug after initial fludarabine therapy for patients with chronic lymphocytic leukemia and low-grade non-Hodgkin's lymphoma.
    Zinzani PL; Levrero MG; Lauria F; Rondelli D; Zaja F; Russo D; Fanin R; De Rossi G; Mauro FR; Bendandi M; Gozzetti A; Dianzani F; Mandelli F; Tura S
    Haematologica; 1994; 79(1):55-60. PubMed ID: 15378949
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Malignant non-Hodgkin's lymphoma of childhood and adolescence in Austria--therapy results between 1986 and 2000.
    Attarbaschi A; Mann G; Dworzak M; Trebo M; Urban C; Fink FM; Horcher E; Reiter A; Riehm H; Gadner H;
    Wien Klin Wochenschr; 2002 Dec; 114(23-24):978-86. PubMed ID: 12635465
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [High dose chemoradiotherapy and autologous bone marrow transplantation (ABMT) as a first line therapy to treat advanced adult high-grade malignant T-cell non-Hodgkin's lymphoma--a pilot clinical study].
    Wu GQ
    Zhonghua Zhong Liu Za Zhi; 1993 Jan; 15(1):47-51. PubMed ID: 7687533
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I/II study of high-dose cyclophosphamide, etoposide and cisplatin followed by autologous bone marrow or peripheral blood stem cell transplantation in patients with poor prognosis Hodgkin's disease or non-Hodgkin's lymphoma.
    Klumpp TR; Mangan KF; Glenn LD; Malaspina DR; Cropper T; Mullaney M; Macdonald JS
    Bone Marrow Transplant; 1993 Oct; 12(4):337-45. PubMed ID: 7506091
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A variant of ProMACE-CytaBOM chemotherapy for non-Hodgkin's lymphoma with threefold higher drug dose size but identical cumulative dose intensity. A pilot study of the Italian lymphoma study group (GISL).
    Gobbi PG; Ghirardelli ML; Avanzini P; Baldini L; Quarta G; Stelitano C; Broglia C; Loni C; Silingardi V; Ascari E
    Haematologica; 2000 Mar; 85(3):263-8. PubMed ID: 10702814
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-dose ifosfamide in combination with etoposide and epirubicin (IVE) in the treatment of relapsed/refractory Hodgkin's disease and non-Hodgkin's lymphoma: a report on toxicity and efficacy.
    Proctor SJ; Taylor PR; Angus B; Wood K; Lennard AL; Lucraft H; Carey PJ; Stark A; Iqbal A; Haynes A; Russel N; Leonard RC; Culligan D; Conn J; Jackson GH
    Eur J Haematol Suppl; 2001 Jul; 64():28-32. PubMed ID: 11486397
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The treatment of relapsed or refractory intermediate grade non-Hodgkin's lymphoma with autologous bone marrow transplantation followed by cyclosporine and interferon.
    Gryn J; Johnson E; Goldman N; Devereux L; Grana G; Hageboutros A; Fernandez E; Constantinou C; Harrer W; Viner E; Goldberg J
    Bone Marrow Transplant; 1997 Feb; 19(3):221-6. PubMed ID: 9028549
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-Dose celecoxib and metronomic "low-dose" cyclophosphamide is an effective and safe therapy in patients with relapsed and refractory aggressive histology non-Hodgkin's lymphoma.
    Buckstein R; Kerbel RS; Shaked Y; Nayar R; Foden C; Turner R; Lee CR; Taylor D; Zhang L; Man S; Baruchel S; Stempak D; Bertolini F; Crump M
    Clin Cancer Res; 2006 Sep; 12(17):5190-8. PubMed ID: 16951238
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum selenium levels in untreated children with acute lymphoblastic leukemia. I.
    Mikac-Dević M; Ferenec D; Tiefenbach A
    J Trace Elem Electrolytes Health Dis; 1990 Mar; 4(1):7-10. PubMed ID: 2135960
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Second lymphoid malignant neoplasms occurring in patients treated for Hodgkin's disease.
    Armitage JO; Dick FR; Goeken JA; Foucar MK; Gingrich RD
    Arch Intern Med; 1983 Mar; 143(3):445-50. PubMed ID: 6338848
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [A preliminary study of chemo-interferon therapy in malignant lymphoma].
    Takeyama H; Yano K; Fukutani H; Watanabe E
    Gan To Kagaku Ryoho; 1987 Jan; 14(1):140-5. PubMed ID: 3800402
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized trial of peripheral blood progenitor cell vs bone marrow as hematopoietic support for high-dose chemotherapy in patients with non-Hodgkin's lymphoma and Hodgkin's disease: a clinical and molecular analysis.
    Kanteti R; Miller K; McCann J; Roitman D; Morelli J; Hurley C; Berkman E; Schenkein D
    Bone Marrow Transplant; 1999 Sep; 24(5):473-81. PubMed ID: 10482930
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The use of betamethasone in polychemotherapy of lymphoproliferative diseases].
    Cellerino R; Ambrosetti A; Tummarello D; Perini A; Piga A; Celebrano M
    Minerva Med; 1980 Sep; 71(32):2293-7. PubMed ID: 6933321
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence of hepatitis C virus infection in lymphoproliferative diseases other than B-cell non-Hodgkin's lymphoma, and in myeloproliferative diseases: an Italian Multi-Center case-control study.
    Bianco E; Marcucci F; Mele A; Musto P; Cotichini R; Sanpaolo MG; Iannitto E; De Renzo A; Martino B; Specchia G; Montanaro M; Barbui AM; Nieddu R; Pagano L; Rapicetta M; Franceschi S; Mandelli F; Pulsoni A;
    Haematologica; 2004 Jan; 89(1):70-6. PubMed ID: 14754608
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunomodulation by recombinant interferon-alpha 2 in a phase I trial in patients with lymphoproliferative malignancies.
    Ozer H; Gavigan M; O'Malley J; Thompson D; Dadey B; Nussbaum-Blumenson A; Snider C; Rudnick S; Ferraresi R; Norred S
    J Biol Response Mod; 1983; 2(6):499-515. PubMed ID: 6607323
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.